GregoryMSullivanMD

Psychiatry • New York, NY

Chief Medical Officer, Tonix Pharmaceuticals, Inc.

Join to view full profile

Dr. Sullivan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sullivan's full profile

Already have an account?

Office
617 W End Ave
Ste 1B
New York, NY 10024
Phone+1 212-579-0339

Fax+1 212-543-5437

Education & Training

New York Presbyterian Hospital (Columbia Campus)/New York State Psychiatric InstituteResidency, Psychiatry, 1994 - 1997
New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1992 - 1993
Columbia University Vagelos College of Physicians and SurgeonsClass of 1992

Certifications & Licensure

NY State Medical License 1995 - 2026

Clinical Trials

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) Start of enrollment: 2013 Sep 01
Completed
Phase 2, Phase 3
12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients Start of enrollment: 2013 Dec 01
Completed
Phase 3
Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions Start of enrollment: 2014 Oct 01
Completed
Phase 2
Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers Start of enrollment: 2014 Nov 01
Completed
Phase 1
Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions Start of enrollment: 2015 Apr 01
Completed
Phase 2
Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache Start of enrollment: 2015 Jun 01
Completed
Phase 2
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia Start of enrollment: 2015 Apr 01
Completed
Phase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD Start of enrollment: 2019 Mar 07
Terminated
Phase 3
A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection Start of enrollment: 2022 Aug 18
Completed
Phase 2
A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia Start of enrollment: 2019 Dec 09
Completed
Phase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia Start of enrollment: 2022 Apr 06
Completed
Phase 3
A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia Start of enrollment: 2020 Jul 22
Completed
Phase 3
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) Start of enrollment: 2023 Mar 02
Completed
Phase 2
A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine Start of enrollment: 2022 Dec 06
Completed
Phase 2
Safety and Efficacy Study of TNX-102 SL in Participants With PTSD Start of enrollment: 2022 Oct 14
Withdrawn
Phase 2
Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens Start of enrollment: 2022 Jan 07
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

38 citations
Life events: a complex role in the timing of suicidal behavior among depressed patients.
Maria A. Oquendo, M. Mercedes Perez-Rodriguez, E Poh, Gregory M. Sullivan, Ainsley K. Burke
Molecular Psychiatry. 2014-08-01
260 citations
Lesions in the bed nucleus of the stria terminalis disrupt corticosterone and freezing responses elicited by a contextual but not by a specific cue-conditioned fear st...
Gregory M. Sullivan, John Apergis, David E. A. Bush, Luke R. Johnson, Mian Hou
Neuroscience. 2004-01-01
17 citations
Higher pretreatment 5-HT1A receptor binding potential in bipolar disorder depression is associated with treatment remission: a naturalistic treatment pilot PET study.
Martin J. Lan, Natalie Hesselgrave, Adam Ciarleglio, R. Todd Ogden, Gregory M. Sullivan
Synapse. 2013-11-01

Press Mentions

Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical PsychopharmacologyMay 30th, 2019
Tonix Pharmaceuticals Will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Military Health System Research SymposiumAugust 15th, 2018
Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual MeetingMay 24th, 2017